Satellos Bioscience Inc. Common Stock (MSLE) - Total Liabilities
Based on the latest financial reports, Satellos Bioscience Inc. Common Stock (MSLE) has total liabilities worth $5.85 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore MSLE long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Satellos Bioscience Inc. Common Stock - Total Liabilities Trend (2007–2025)
This chart illustrates how Satellos Bioscience Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Satellos Bioscience Inc. Common Stock balance sheet assets.
Satellos Bioscience Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Satellos Bioscience Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kimteks Poliuretan Sanayi ve Ticaret AS
IS:KMPUR
|
Turkey | TL8.27 Billion |
|
Intops Co. Ltd
KQ:049070
|
Korea | ₩121.40 Billion |
|
Sangsin Energy Display Precision Co.Ltd
KQ:091580
|
Korea | ₩215.42 Billion |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
Thailand | ฿16.46 Billion |
|
Studsvik AB
ST:SVIK
|
Sweden | Skr618.90 Million |
|
NORTHERN OCEAN LTD.
F:4JO
|
Germany | €178.21 Million |
|
Nucleus Software Exports Limited
NSE:NUCLEUS
|
India | Rs3.59 Billion |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
USA | $7.36 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Satellos Bioscience Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Satellos Bioscience Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Satellos Bioscience Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Satellos Bioscience Inc. Common Stock (2007–2025)
The table below shows the annual total liabilities of Satellos Bioscience Inc. Common Stock from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.11 Million | +14.29% |
| 2024-12-31 | $3.59 Million | -0.89% |
| 2023-12-31 | $3.62 Million | +29.35% |
| 2022-12-31 | $2.80 Million | +69.78% |
| 2021-12-31 | $1.65 Million | +25.37% |
| 2020-12-31 | $1.32 Million | +58.65% |
| 2019-12-31 | $829.64K | +3.69% |
| 2018-12-31 | $800.13K | +173.54% |
| 2017-12-31 | $292.51K | +110.07% |
| 2016-12-31 | $139.24K | +21.17% |
| 2015-12-31 | $114.92K | -92.37% |
| 2014-12-31 | $1.51 Million | -39.67% |
| 2013-12-31 | $2.50 Million | +158.55% |
| 2012-12-31 | $965.94K | +279.37% |
| 2011-12-31 | $254.62K | -13.19% |
| 2010-12-31 | $293.31K | -9.20% |
| 2009-12-31 | $323.03K | -16.59% |
| 2008-12-31 | $387.29K | -50.40% |
| 2007-12-31 | $780.80K | -- |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more